IRS4 Antibody

What is IRS4 and what are its primary functions in cellular signaling?

IRS4 (Insulin Receptor Substrate 4) functions as a critical interface between multiple growth factor receptors with tyrosine kinase activity, including insulin receptor, IGF1R, and FGFR1, and a complex network of intracellular signaling molecules containing SH2 domains . It plays a central role in the IGF1R mitogenic signaling pathway and promotes the AKT1 signaling pathway and BAD phosphorylation during insulin stimulation without activating RPS6KB1 or inhibiting apoptosis . Interaction between IRS4 and GRB2 enhances insulin-stimulated mitogen-activated protein kinase activity, contributing to cell growth and proliferation . Additionally, IRS4 plays pivotal roles in growth, reproduction, and glucose homeostasis while potentially acting as a negative regulator of the IGF1 signaling pathway by suppressing the functions of IRS1 and IRS2 .

How does IRS4 differ structurally and functionally from other insulin receptor substrate proteins?

Unlike other IRS family members, IRS4 can induce constitutive PI3K/AKT hyperactivation and cell proliferation even in the absence of insulin or growth factors, suggesting unique structural elements that contribute to its distinct signaling properties . The protein has a molecular mass of approximately 133.8 kilodaltons and contains specific phosphorylation sites that regulate its activity and stability . While IRS1 and IRS2 are widely expressed and have well-established roles in metabolic homeostasis, IRS4 expression is more restricted and shows distinct regulatory patterns . Additionally, IRS4 may actually counteract other IRS proteins by functioning as a negative regulator of the IGF1 signaling pathway through suppression of IRS1 and IRS2 functions, highlighting its complementary rather than redundant role in insulin signaling networks .

What are the primary applications for IRS4 antibodies in cellular research?

IRS4 antibodies are primarily utilized in Western blotting (WB), immunoprecipitation (IP), immunohistochemistry (IHC), immunocytochemistry (ICC), and immunofluorescence (IF) applications, allowing researchers to detect, quantify, and visualize IRS4 protein in various experimental contexts . In signaling pathway research, these antibodies enable investigation of IRS4's interactions with upstream receptors and downstream effectors through co-immunoprecipitation experiments . For cancer research, IRS4 antibodies facilitate the examination of protein expression levels in tumor samples and cell lines, particularly in osteosarcoma where IRS4 levels correlate with disease progression . Additionally, phospho-specific antibodies like anti-p-IRS4-S859 allow researchers to study post-translational modifications that regulate IRS4 function and stability in various physiological and pathological conditions .

What cell lines are most appropriate for studying IRS4 signaling and antibody validation?

DMS114, HEK293T, and 293AAV cell lines have been extensively documented in IRS4 research and are considered reliable models for studying IRS4 signaling and validating antibody specificity . These cell lines demonstrate measurable IRS4 expression levels that can be effectively modulated through siRNA knockdown approaches, making them ideal for functional studies . In cancer research contexts, osteosarcoma cell lines are particularly valuable as they exhibit variable IRS4 expression levels that correlate with CK1γ2 expression, providing a platform for investigating regulatory mechanisms . When selecting appropriate cell lines, researchers should consider endogenous IRS4 expression levels, the presence of required signaling components (insulin receptor, IGF1R, FGFR1), and the experimental readout system (e.g., AKT phosphorylation, cell proliferation) to ensure meaningful and reproducible results .

How can phosphorylation status of IRS4 be effectively assessed using antibody-based methods?

To assess IRS4 phosphorylation status, researchers can employ phospho-specific antibodies targeting key regulatory sites, such as the anti-p-IRS4-S859 antibody that recognizes CK1γ2-mediated phosphorylation . The methodological approach involves:

• Sample preparation: Extract proteins using phosphatase inhibitor-supplemented lysis buffers to preserve phosphorylation state

• Immunoprecipitation: Enrich IRS4 protein from complex lysates using validated anti-IRS4 antibodies

• Western blotting: Analyze using phospho-specific antibodies alongside total IRS4 antibodies to normalize for expression levels

• Validation: Include appropriate controls such as phosphatase-treated samples and phosphorylation-site mutants (e.g., IRS4-S859A) to confirm specificity

For in vitro assessment, kinase assays can be performed using purified components, where IRS4 wild-type protein is incubated with active CK1γ2 and ATP, followed by detection with phospho-specific antibodies . This approach should be complemented with mass spectrometry analysis for comprehensive phosphorylation site mapping in more advanced research contexts .

What experimental design is recommended for studying IRS4 degradation pathways?

To study IRS4 degradation pathways, researchers should implement a multi-faceted experimental approach combining protein stability assays, ubiquitination analysis, and lysosomal/proteasomal inhibition studies . The recommended experimental design includes:

• Protein stability assessment: Treat cells with cycloheximide to inhibit protein synthesis, then monitor IRS4 protein levels over time using Western blotting to determine half-life

• Ubiquitination analysis: Perform immunoprecipitation of IRS4 followed by ubiquitin detection, or use His-tagged ubiquitin pulldown assays

• Pathway identification: Apply specific inhibitors of lysosomal (e.g., chloroquine, bafilomycin A1) or proteasomal (e.g., MG132) degradation pathways to identify the primary route of IRS4 turnover

• E3 ligase identification: Use immunoprecipitation coupled with mass spectrometry to identify potential E3 ligases (such as CHIP) that regulate IRS4 polyubiquitination

• Phosphorylation dependence: Compare degradation rates between wild-type IRS4 and phosphorylation-site mutants (e.g., IRS4-S859A) to establish the relationship between phosphorylation and protein stability

This comprehensive approach has successfully revealed that IRS4 degradation occurs primarily through the ubiquitin/lysosome pathway regulated by CHIP E3 ligase activity following CK1γ2-mediated phosphorylation at Ser859 .

How does CK1γ2-mediated phosphorylation alter IRS4 signaling capacity and protein stability?

CK1γ2-mediated phosphorylation of IRS4 at Ser859 serves as a critical regulatory switch that fundamentally alters both signaling capacity and protein stability . This phosphorylation event creates a recognition site for CHIP E3 ligase binding, which subsequently catalyzes the polyubiquitination of IRS4, targeting it for degradation through the ubiquitin/lysosome pathway . In functional terms, the phosphorylation-deficient IRS4-S859A mutant demonstrates enhanced stability and induces significantly higher levels of Akt phosphorylation compared to wild-type IRS4, indicating that CK1γ2-mediated phosphorylation acts as a negative regulator of IRS4 signaling output . This regulatory mechanism appears particularly relevant in cancer contexts, as experimental data from osteosarcoma models demonstrate that cells expressing non-phosphorylatable IRS4 mutants display accelerated proliferation and enhanced tumorigenic potential both in vitro and in xenograft models . The negative correlation between CK1γ2 and IRS4 protein levels observed in osteosarcoma clinical samples further supports the significance of this regulatory axis in disease progression .

What methodologies can resolve contradictory findings in IRS4 signaling studies?

Resolving contradictory findings in IRS4 signaling studies requires a multi-faceted methodological approach that addresses biological context, experimental conditions, and technical limitations . Researchers should implement:

• Cell type standardization: Use multiple cell lines with defined IRS4 expression levels to account for cell-specific signaling architectures

• Expression level control: Employ inducible expression systems to achieve physiologically relevant protein levels and avoid overexpression artifacts

• Temporal resolution: Implement time-course analyses to capture dynamic signaling events that may be missed at single time points

• Pathway component analysis: Systematically evaluate the expression and activation status of key signaling nodes in the insulin/IGF pathway

• Post-translational modification mapping: Use phospho-specific antibodies and mass spectrometry to comprehensively assess IRS4 modifications

• Genetic validation: Apply CRISPR/Cas9 gene editing for complete IRS4 knockout followed by rescue experiments with wild-type or mutant constructs

This approach has helped reconcile seemingly contradictory observations regarding IRS4's role in the PI3K/AKT pathway activation, demonstrating that IRS4 can function as both a positive regulator through direct PI3K recruitment and a negative regulator by suppressing IRS1/IRS2 function depending on cellular context and expression levels .

How can researchers differentiate between direct and indirect effects of IRS4 on PI3K/AKT signaling?

Differentiating between direct and indirect effects of IRS4 on PI3K/AKT signaling requires sophisticated experimental approaches that isolate specific protein interactions and signaling events . The recommended methodological framework includes:

• Domain-specific mutagenesis: Create IRS4 constructs with mutations in key binding domains (e.g., PI3K binding sites, SH2 domain interaction motifs) to dissect direct interaction requirements

• Sequential knockdown/rescue experiments: Deplete IRS family members individually and in combination, followed by rescue with wild-type or mutant IRS4 to reveal compensatory mechanisms

• Proximity ligation assays: Visualize direct protein interactions between IRS4 and pathway components in situ using antibody-based detection methods

• Temporal signaling analyses: Implement rapid time-course studies with phospho-specific antibodies to determine the sequence of activation events following stimulation

• In vitro reconstitution: Reconstruct minimal signaling complexes using purified components to establish direct biochemical relationships

Studies employing these approaches have revealed that IRS4 can directly activate PI3K/AKT signaling through physical recruitment of p85 regulatory subunits while simultaneously modulating the function of IRS1/IRS2, demonstrating both direct and indirect regulatory mechanisms . The balance between these effects appears to be context-dependent and influenced by the relative expression levels of different IRS family members, explaining some of the contradictory observations in different experimental systems .

What are the most common sources of false results when using IRS4 antibodies, and how can researchers avoid them?

When working with IRS4 antibodies, researchers frequently encounter false results stemming from several key issues . Cross-reactivity with other IRS family members represents a significant concern due to sequence homology, particularly in conserved domains . To mitigate this, researchers should validate antibody specificity using IRS4 knockout/knockdown samples and perform comprehensive cross-reactivity testing against recombinant IRS1, IRS2, and IRS3 proteins .

Epitope masking through post-translational modifications or protein-protein interactions can lead to false negatives, especially when the antibody recognition site coincides with phosphorylation sites or interaction domains . This can be addressed by using multiple antibodies targeting different epitopes and employing appropriate sample preparation methods that disrupt protein complexes .

Detection sensitivity limitations may arise when working with tissues or cell lines with naturally low IRS4 expression levels . Researchers can overcome this by implementing signal amplification techniques, optimizing protein extraction protocols specifically for phosphoproteins, and using more sensitive detection methods like enhanced chemiluminescence or fluorescent secondary antibodies .

How should researchers optimize immunohistochemistry protocols for IRS4 detection in different tissue samples?

Optimizing immunohistochemistry (IHC) protocols for IRS4 detection requires systematic adjustment of key parameters to account for tissue-specific characteristics . The optimized methodology includes:

• Fixation optimization: Compare different fixation methods (e.g., 10% neutral buffered formalin, paraformaldehyde, alcohol-based fixatives) and durations to preserve epitope integrity

• Antigen retrieval refinement: Test multiple methods including heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) with variable heating times

• Blocking optimization: Use 5-10% normal serum from the same species as the secondary antibody with 0.1-0.3% Triton X-100 for permeabilization

• Antibody titration: Determine optimal primary antibody concentration through serial dilutions (typically 1:50 to 1:1000)

• Detection system selection: Compare DAB-based systems with fluorescent methods for sensitivity and specificity

• Counterstaining adaptation: Adjust hematoxylin counterstaining intensity based on tissue type

The semi-quantitative scoring system using both staining intensity (weak=1, moderate=2, strong=3) and percentage of positive areas (0%=0, <10%=1, 10-50%=2, 51-80%=3, >80%=4) provides a reproducible method for IRS4 expression evaluation across different tissue samples . This approach allows for reliable classification of IRS4 expression as high (scores 8-12) or low (scores 0-6) for correlation with clinical parameters or experimental variables .

What controls should be included when validating new IRS4 antibody lots for research applications?

Comprehensive validation of new IRS4 antibody lots requires inclusion of multiple control types to ensure reproducibility and reliability of experimental results . The essential controls include:

• Positive and negative cell line controls: Include cell lines with documented high IRS4 expression (e.g., DMS114, HEK293T) and those with low/absent expression or siRNA-mediated knockdown

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm binding specificity

• Recombinant protein standards: Use purified recombinant IRS4 at known concentrations for sensitivity determination and batch-to-batch comparison

• Cross-reactivity panel: Test against other IRS family members (IRS1, IRS2, IRS3) to assess specificity

• Application-specific controls:

  • Western blot: Include molecular weight markers and lysates from IRS4-transfected cells

  • IHC/ICC: Process serial sections/cells with isotype control antibodies and without primary antibody

  • IP: Perform parallel IPs with non-specific IgG and validate pulled-down proteins by mass spectrometry

For phospho-specific antibodies like anti-p-IRS4-S859, additional controls should include phosphatase-treated samples and expression of phospho-mutant constructs (e.g., IRS4-S859A) to confirm specificity for the phosphorylated epitope . Documentation of all validation steps with quantifiable metrics enables objective assessment of antibody performance and facilitates troubleshooting if performance changes over time .

How can IRS4 antibodies be used to investigate the role of IRS4 in tumor progression and therapeutic resistance?

IRS4 antibodies provide essential tools for investigating the complex role of IRS4 in tumor progression and therapeutic resistance through multiple experimental approaches . Immunohistochemical profiling using validated IRS4 antibodies enables researchers to establish correlations between IRS4 expression levels and clinicopathological features across tumor types, as demonstrated in osteosarcoma studies where IRS4 expression inversely correlates with CK1γ2 levels and associates with disease progression . Functional studies combining IRS4 antibodies with phospho-specific antibodies against downstream signaling nodes (p-AKT, p-ERK) allow for mechanistic investigation of how IRS4 hyperactivation contributes to sustained PI3K/AKT signaling even in the absence of growth factors, potentially explaining therapeutic resistance to receptor-targeted therapies .

For therapy resistance mechanisms, researchers can implement longitudinal sampling approaches where IRS4 antibodies are used to track expression changes before, during, and after treatment failure, potentially identifying IRS4 upregulation as an adaptive response . The development of therapeutic resistance models through chronic drug exposure followed by comparative IRS4 pathway analysis between parental and resistant cells can reveal whether IRS4 signaling represents a bypass mechanism for targeted therapy resistance, guiding combination treatment strategies targeting both the primary oncogenic driver and the IRS4 compensatory pathway .

What experimental approaches can quantitatively assess the impact of IRS4 phosphorylation on cellular signaling dynamics?

Quantifying the impact of IRS4 phosphorylation on signaling dynamics requires sophisticated technological approaches that capture both the temporal and spatial aspects of signal transduction . A comprehensive experimental framework includes:

Studies using these approaches have revealed that CK1γ2-mediated phosphorylation of IRS4 at Ser859 significantly alters signaling dynamics by accelerating protein degradation through the ubiquitin/lysosome pathway, resulting in attenuated PI3K/AKT signaling over time . The non-phosphorylatable IRS4-S859A mutant exhibits prolonged signaling activity, leading to enhanced cell proliferation and tumorigenesis in experimental models .

How might future developments in antibody engineering improve IRS4 research capabilities?

Future developments in antibody engineering hold significant promise for advancing IRS4 research capabilities across multiple dimensions . The development of conformation-specific antibodies that selectively recognize active versus inactive IRS4 structural states would enable researchers to directly assess the proportion of signaling-competent protein under various conditions without relying solely on downstream pathway activation as a proxy . Multiplexed epitope detection through multicolor labeling of different IRS4 domains and phosphorylation sites could provide simultaneous visualization of multiple regulatory events within individual cells, revealing potential cooperative effects between different post-translational modifications .

Intrabody development—antibodies engineered to function within living cells—would allow real-time tracking of IRS4 localization, conformational changes, and protein-protein interactions in intact cellular systems, potentially revealing dynamic regulatory mechanisms invisible to conventional biochemical approaches . Antibody-drug conjugates targeting IRS4 could serve dual research and therapeutic purposes by enabling selective modulation or elimination of IRS4-expressing cells in complex systems, particularly valuable for studying IRS4's role in heterogeneous tumor environments .

Nanobody development (single-domain antibodies derived from camelid antibodies) against IRS4 epitopes would provide superior tissue penetration for imaging applications and potentially overcome steric hindrances that prevent conventional antibodies from accessing certain epitopes, especially in densely packed protein complexes . These innovations collectively promise to overcome current technical limitations and enable more sophisticated investigations into IRS4 biology in both normal physiology and disease states.